Staar Surgical Board Authorizes $50 Million Share Buyback Program
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-27. Check what remains unresolved below before relying on it.
What does this change in the investment case for Staar Surgical Company?
Open-market share repurchases reduce STAA float and increase EPS accretion, providing direct demand support following the 7.5% rally.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factStaar Surgical announced a $50 million share repurchase program authorized by its board of directors. |
| What else was confirmed? | Reported factCompany shares rallied 7.5% on Friday following the capital return disclosure. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for STAA yet — this is the next research task. |
| What would change the assessment? | UnknownStaar Surgical Buyback Pace & 10-Q Disclosures — Execution cadence and remaining authorized capacity under the $50M program. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Staar Surgical announced a $50 million share repurchase program authorized by its board of directors.
- · Company shares rallied 7.5% on Friday following the capital return disclosure.
- · Executive leadership cited balance sheet strength, free cash flow conversion, and valuation disconnect as rationale for the authorization.
Public research record
Research framework · page evidenceCompleted event assessment
open-market buyback execution reducing public float and signaling balance sheet confidence
| Type | Claim | Scope |
|---|---|---|
| Assumption | Staar Surgical announced a $50 million share repurchase program authorized by its board of directors. | 2026-09-27 |
| Interpretation | open-market buyback execution reducing public float and signaling balance sheet confidence | STAA |
Countercase, invalidators, and sources
Management aggressively executes the $50M buyback, reducing share count and defending the stock against broader small-cap volatility.
- · Staar Surgical Buyback Pace & 10-Q Disclosures — Execution cadence and remaining authorized capacity under the $50M program.
- Why Staar Surgical Stock Soared Today · 2026-09-25
What remains unresolved
- Base path
- Repurchases are executed opportunistically across several quarters as free cash flow allows.
- Adverse path
- End-market ophthalmic procedure volumes soften, constraining free cash flow and slowing actual buyback pace.
- Supportive path
- Management aggressively executes the $50M buyback, reducing share count and defending the stock against broader small-cap volatility.
- · Staar Surgical Buyback Pace & 10-Q Disclosures — Execution cadence and remaining authorized capacity under the $50M program.this week
Evidence
- Why Staar Surgical Stock Soared Today2026-09-25
“Staar Surgical announced a $50 million share buyback program authorized by its board, causing the stock to surge 7.5% on Friday. The company's CEO cited confidence in the business, strong balance sheet, and ample free cash flow...”
Supports: Staar Surgical announced a $50 million share buyback program authorized by its board, causing the stock to surge 7.5%.